Cybin announces agreement with fluence to support scaling of embark training for cyb003 phase 3 trial

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling of cybin's embark facilitator training program in preparation for a multi-site, global phas.
CYBN Ratings Summary
CYBN Quant Ranking